Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Royalty Pharma to Present at Upcoming Investor Conferences

GlobeNewswire May 13, 2024

Royalty Pharma Reports First Quarter 2024 Results

GlobeNewswire May 9, 2024

Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab

GlobeNewswire May 9, 2024

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire April 19, 2024

Royalty Pharma Declares Second Quarter 2024 Dividend

GlobeNewswire April 17, 2024

Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Royalty Pharma Reports Q4 and Full Year 2023 Results

GlobeNewswire February 15, 2024

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

GlobeNewswire January 30, 2024

Royalty Pharma Announces Dividend Increase

GlobeNewswire January 19, 2024

Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2024

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

GlobeNewswire November 27, 2023

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

GlobeNewswire November 13, 2023

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Business Wire November 13, 2023

Royalty Pharma Reports Third Quarter 2023 Results

GlobeNewswire November 8, 2023

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

GlobeNewswire October 19, 2023

Royalty Pharma Declares Fourth Quarter 2023 Dividend

GlobeNewswire October 16, 2023

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

GlobeNewswire October 11, 2023

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

GlobeNewswire September 21, 2023

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

GlobeNewswire September 5, 2023

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

GlobeNewswire September 5, 2023